National Cancer Database analysis of gallbladder cancer: Evaluating survival benefit of chemotherapy in early-stage gallbladder cancer

Table 1 Demographic of patients with stage II gallbladder cancer from 2010 to 2017, n (%)

Characteristic	Surgery only (n = 565)	Surgery and chemotherapy (n = 328)	P value
Age (years)			< 0.0001
75-90	267 (47.2)	59 (18.0)
65-74	153 (27.1)	112 (34.1)
55-64	95 (16.8)	90 (27.4)
< 55	50 (8.8)	67 (20.4)
Sex			0.09
Male	164 (29.0)	98 (29.6)
Female	401 (71.0)	231 (70.4)
Race			0.46
Black	82 (15.6)	57 (17.4)
White	442 (78.2)	245 (74.7)
Other/unknown	41 (0.1)	26 (7.9)
Hispanic ethnicity			0.69
Non-Hispanic	476 (84.4)	269 (85.1)
Hispanic	71 (12.6)	47 (14.9)
Geography			0.80
Urban/rural	65 (11.9)	40 (12.5)
Metro	480 (88.1)	280 (87.5)
Facility type			0.12
Community cancer	52 (9.3)	22 (6.8)
Comprehensive community	214 (38.3)	110 (34.2)
Integrated network	104 (18.6)	79 (24.5)
Academic/research	189 (33.8)	111 (34.5)
Insurance			< 0.0001
Medicaid/Medicare/government	406 (71.9)	194 (59.1)
Private	128 (22.7)	121 (36.9)
None/unknown	31 (5.5)	13 (4.0)
Charlson-Deyo score			0.07
0	351 (62.1)	230 (70.1)
1	150 (26.5)	75 (22.9)
2	42 (7.4)	16 (4.9)
3 +	22 (3.9)	7 (2.1)
Surgical management1			< 0.0001
Partial hepatectomy	113 (20.0)	124 (37.8)
Wedge resection	56 (9.9)	49 (14.9)
Lobectomy	6 (1.1)	2 (0.6)
Non liver resection	(69.0)	153 (46.6)

¹Surgical management in addition to cholecystectomy.